<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMM</journal-id><journal-title-group><journal-title>Open Journal of Medical Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3372</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmm.2022.124011</article-id><article-id pub-id-type="publisher-id">OJMM-120913</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Aqueous Leaves Extract of &lt;i&gt;Gongronema latifolium&lt;/i&gt; (Benth) Downregulates the Expression of IFN-γ, IL-10 and Cell Surface Markers in Rabbits
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adekunle</surname><given-names>Babajide Rowaiye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moses</surname><given-names>Njoku</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Angus</surname><given-names>Nnamdi Oli</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nwamaka</surname><given-names>Henrietta Igbokwe</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Titilayo</surname><given-names>Asala</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Suliat</surname><given-names>Adebola Salami</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ikemefuna</surname><given-names>Chijioke Uzochukwu</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Charles</surname><given-names>Okechukwu Esimone</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib></contrib-group><aff id="aff6"><addr-line>Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu, Nigeria</addr-line></aff><aff id="aff7"><addr-line>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu, Nigeria</addr-line></aff><aff id="aff4"><addr-line>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmacy, College of Medicine Campus, University of Lagos, Akoka, Nigeria</addr-line></aff><aff id="aff5"><addr-line>Bio-Entrepreneurship and Extension Services Department, National Biotechnology Development Agency, Abuja, Nigeria</addr-line></aff><aff id="aff3"><addr-line>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe 
University, Agulu, Nigeria</addr-line></aff><aff id="aff2"><addr-line>Department of Pharmaceutical Microbiology and Biotechnology, Nigerian Institute of Pharmaceutical Research &amp;amp; Development, Abuja, Nigeria</addr-line></aff><aff id="aff1"><addr-line>Department of Medical Biotechnology, National Biotechnology Development Agency, Abuja, Nigeria</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>10</month><year>2022</year></pub-date><volume>12</volume><issue>04</issue><fpage>117</fpage><lpage>128</lpage><history><date date-type="received"><day>3,</day>	<month>September</month>	<year>2022</year></date><date date-type="rev-recd"><day>28,</day>	<month>October</month>	<year>2022</year>	</date><date date-type="accepted"><day>1,</day>	<month>November</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Background:</b>
   The pathophysiology of the inflammatory process reveals intricate signaling which include
  s
   the IL-1β, IL-6, and TNFα pathways that could serve as drug targets. Aim: This study determined the effect of the aqueous extract of Gongronema latifolium (AEGL)
   
  leaves on the expression of IFNγ, IL-10, CD3, and CD56 in rabbits. <b>Materials</b> <b>and</b> <b>Methods:</b> ELISA tests were performed to determine the effect of the AEGL on the expression of a pro-inflammatory cytokine (IFNγ), an anti-inflammatory cytokine (IL-10), and CD3 and CD56 cell surface markers in rabbits. Twenty cross-bred male rabbits with an average weight range of 1.0 - 1.5 kg were selected. The rabbits were separated into four groups of four rabbits each treated as follows: Grp1 is the untreated control; Grp2 is the treated control; and Grp3, Grp4, and Grp5 were treated with 200, 400, and 600 mg/kg of AEGL respectively for 28 days. <b>Results:</b> The AEGL showed its greatest inhibitory effect in Group 4 on IL-10 (118.5 pg/ml), and IFNγ (332 pg/ml) on days 14 and 21 respectively. AEGL also showed the highest inhibition of CD3 expression on days 14 and 21 (0 pg/ml) in Group 3; and CD56 expression on day 21 (630.5 pg/ml) in Group 4. <b>Conclusion:</b> AEGL showed exhibited strong T cell mediated anti-
   
  inflammatory, and immunomodulatory activity in test rabbits within the 28-day period which can be confirmed by cell based assays. Specifically at 400 mg/kg, AEGL exhibited the greatest anti-inflammatory activity which is suggestive of its maximum effective dose.
 
</p></abstract><kwd-group><kwd>Inflammation</kwd><kwd> Cell Surface Markers</kwd><kwd> Antioxidant Activity</kwd><kwd> Cytokine</kwd><kwd> Hepatic Toxicity</kwd><kwd> Medicinal Plant</kwd><kwd> &lt;i&gt;Gongronema latifolium&lt;/i&gt;</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Inflammation is an intricate biological process that involves the protection of the body from invading factors and at times marks the onset and/or the progression of diseases [<xref ref-type="bibr" rid="scirp.120913-ref1">1</xref>]. Inflammation involves a vast array of cells, cytokines, chemokines, acute phase proteins, cell surface markers, and immune mediators [<xref ref-type="bibr" rid="scirp.120913-ref2">2</xref>]. The inhibition of any specific protein in these cascades could serves as a viable drug target in the alleviation of inflammatory conditions. To maintain homeostasis, anti-inflammation is facilitated by certain cytokines and mediators and intricate signaling pathways [<xref ref-type="bibr" rid="scirp.120913-ref2">2</xref>]. In order to promote anti-inflammation, these immune agents must be activated. Food, herbs, drugs, and biologics offer a vast array of small molecules, peptides and proteins that have either pro- or anti-inflammatory activity [<xref ref-type="bibr" rid="scirp.120913-ref3">3</xref>].</p><p>The T Lymphocytes (T cells) and Natural Killer (NK) cells with CD3 and CD56 markers respectively are important players in the adaptive immune system. Through the production of cytokines and other immune mediators, they play crucial role in the process of inflammation and immunomodulation [<xref ref-type="bibr" rid="scirp.120913-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref5">5</xref>]. IFN-γ and IL-10 are key cytokines that alter the immune system with their pro-inflammatory and anti-inflammatory activities respectively [<xref ref-type="bibr" rid="scirp.120913-ref6">6</xref>]. The IL-10 or human cytokine synthesis inhibitory factor (CSIF) is a multifunctional cytokine that regulates immune and inflammatory responses. It is an anti-inflammatory cytokine which is released during systemic infections. It is produced by NKC cells, macrophages, dendritic cells (DC), B cells, and CD4+ T cells (Th2) [<xref ref-type="bibr" rid="scirp.120913-ref7">7</xref>]. IL-10 exerts pleiotropic effects on hemopoietic and non-hemopoietic cells such as by endothelial cells and keratinocytes [<xref ref-type="bibr" rid="scirp.120913-ref7">7</xref>]. It affects immunosuppression by the inhibition of the effector functions of NKC cells, macrophages, monocytes and Th1 cells. It does this by inhibiting the maturation and differentiation of these haemopoeitic cells and subsequently their cytokines and chemokines [<xref ref-type="bibr" rid="scirp.120913-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref8">8</xref>]. IL10 binds to and forms a complex with its receptors which consists of two IL-10R1 and two IL-10R2 molecules and the receptors so activated, trigger several signaling pathways which include the Jak1-Tyk2/Stat3 pathway [<xref ref-type="bibr" rid="scirp.120913-ref8">8</xref>].</p><p>IFNγ inhibits the proliferation of Th2 cells and enhances the proliferation of activated B cells. IFN-γ is expressed by NK cells and is involved in tumor immune surveillance through cytostatic and cytotoxic mechanisms [<xref ref-type="bibr" rid="scirp.120913-ref9">9</xref>]. It could have either pro or anti tumorigenic activity depending on cellular or molecular microenvironment of the tumor [<xref ref-type="bibr" rid="scirp.120913-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref10">10</xref>]. It also inhibits tumor development by providing protection through lymphocytes and by immunoediting of the cancer cell phenotype [<xref ref-type="bibr" rid="scirp.120913-ref7">7</xref>]. Due to the tumor-sculpting roles of immunity, IFN γ is been proven to be involved in cancer immunoediting and not cancer immunosurveilance [<xref ref-type="bibr" rid="scirp.120913-ref9">9</xref>].</p><p>Extracts of Gongronema latifolium (AEGL) has been reported to show anti-inflammatory and antioxidant activities [<xref ref-type="bibr" rid="scirp.120913-ref11">11</xref>]. This study is aimed at investigating the anti-inflammatory properties of AEGL through its effect on the expression of IFNγ, and IL-10; and to trace the cellular sources of these cytokines through the expression of CD3, and CD56 in rabbits.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Experimental Animals</title><p>Twenty cross-bred male rabbits with an average weight range of 1.0 - 1.5 kg were selected. The 20 were reared at the Bioresources Development Centre, Isanlu (Kogi state, Nigeria). During the experimental period, the rabbits were housed in steel wired mesh cage measuring 50 cm &#215; 50 cm &#215; 40 cm at the well-ventilated Animal Facility Centre of the Nigerian Institute of Pharmaceutical Research and Development (NIPRD). Two weeks prior to the commencement of the study, the rabbits which were in good health were kept in the cages and no drugs were administered. The housing had a 12-hour light/dark cycle, a relative humidity between 36% - 40%, and a temperature of 28˚C &#177; 2˚C. The study rabbits were administered roughage, commercial grower pelleted feed, and water ad libitum. The design of the experiment and handling of the rabbits was in accordance with international standard [<xref ref-type="bibr" rid="scirp.120913-ref12">12</xref>].</p></sec><sec id="s2_2"><title>2.2. Preparation of an Aqueous Extract of Gongronema latifolium</title><p>The leaves of the edible plant, Gongronema latifolium were obtained from a local farm in Ohafia, Abia state of Nigeria. The plant was taxonomically identified by the Herbarium of NIPRD and voucher number (NIPRD/H/6968) was issued. The leaves which had been dried at room temperature for 4 weeks was destalked and pulverized. For a period of 24 hours, 1.8 kg of dried Gongronema latifolium leaves was soaked in 24 L of water and agitated with a mechanical shaker (Karl Kolb Scientific Supplies, Germany). The solution was carefully filtered, and the filtrate was concentrated using a rotary evaporator (Bibby Sterlin Ltd., Staffordshire, England). The extract was stored at 4˚C in a refrigerator. Using distilled water, different concentrations of the extract was prepared [<xref ref-type="bibr" rid="scirp.120913-ref13">13</xref>].</p></sec><sec id="s2_3"><title>2.3. Experimental Design</title><p>The rabbits were separated into five groups of four rabbits each and treated as follows: Group 1 is the Untreated Control (with no extract and no multivitamins); Group 2 is the treated Control (administered or treated with 0.33 ml of Multivitamins (EMVITE<sup>&#174;</sup> Multivitamin Syrup) per kg body weight); Group 3 is treated with 200 mg/kg of AEGL; Group 4 is treated with 400 mg/kg of AEGL; and Group 5 is treated with 600 mg/kg of AEGL. Animals were weighed weekly and different doses of the aqueous extract of the plant were administered to the rabbits daily by intubation for 28 days.</p></sec><sec id="s2_4"><title>2.4. Sample Collection, Preparation and Testing</title><p>Blood samples were collected from the lateral saphenous and ear veins of the rabbits at day 0, 7, 14, 21, and 28 of the administration of the AEGL. The plasma was obtained after centrifuging the blood at 2000 rpm for 10 minutes with Eppendorf Centrifuge 5702 (Eppendorf AG 22331, Hamburg, Germany).</p><p>The study samples and the IFNγ, Il-10 and CD56 ELISA kits (Elabscience, China) were removed from the refrigerator and kept at room temperature for 20 minutes before the commencement of the experiment. 30 ml of Concentrated Wash Buffer (Elabscience, China) was diluted with 720 ml of deionized water (dilution factor of 25). 1 ml of Reference Standard &amp; Sample Diluent (Elabscience, China) was added to the Standard (Elabscience, China) which had already been centrifuged for 1 minute. This standard working solution (1000 pg/ml) was allowed to stand for 10 minutes and diluted into different concentrations. For the dilution, the Reference Standard &amp; Sample Diluent (Elabscience, China) was used to obtain 1000, 500, 250, 125, 62.5, 31.25, 15.63 and 0 pg/ml. To produce a Biotinylated detection Antibody (Elabscience, China) working solution, the Concentrated Biotinylated Detection Antibody (Elabscience, China) was centrifuged and diluted by a factor of 100 using the Biotinylated Detection Antibody Diluent (Elabscience, China). Also, to produce the Concentrated HRP Conjugate working solution (Elabscience, China), the HRP Conjugate (Elabscience, China) was diluted by a factor of 100 using the HRP conjugate Diluent (Elabscience, China). To each well, 100 μL of sample was added and incubated (DNP-9082 Laboratory Incubator) at 37˚C for 90 minutes. The liquid was removed from the wells, 100 μL of Biotinylated Detection antibody (Elabscience, China) was added, and incubated at 37˚C for 60 minutes. The solution was aspirated, and wells were washed thrice. 100 μL of HRP Conjugate (Elabscience, China) was added to the wells, incubated at 37˚C for 30 min, removed, and washed five times. 90 μL of Substrate Reagent (Elabscience, China) was added to the wells, incubated at 37˚C for 15 min, and 50 μL of Stop Solution (Elabscience, China) was added. At 450 nm wavelength, the optical density of the solution was read immediately with the GF-N3000 Microplate reader, (England) and the results calculated.</p><p>The CD3 kit (Bioassay Technology Laboratory, China) was removed from the refrigerator and kept at room temperature for 20 minutes before use. To produce 640 ng/ml standard stock solutions, 120 μL of Standard diluent (Bioassay Technology Laboratory, China) was added to 120 μL of standard (1280 ng/ml) (Bioassay Technology Laboratory, China). The solution was allowed to stand for 15 minutes before it was serially diluted. 320, 160, 80 and 40 ng/ml solutions were produced. Also, 20 ml of wash buffer concentrate (Bioassay Technology Laboratory, China) was added to 480 ml of wash buffer (Bioassay Technology Laboratory, China). 50 μL of standard solution (Bioassay Technology Laboratory, China) was added into the standard well. 10 μL anti-CD3 antibodies (Bioassay Technology Laboratory, China) were added to 40 μL of sample in the sample wells. To both sample and standard wells, 50 μL of streptuavidin HRP (Bioassay Technology Laboratory, China) was added. The plate was agitated for thorough mixing, covered, and incubated for 60 minutes at 37˚C. With the buffer solution, the plate was washed five times and blotted with paper towel. To each well, 50 μL of Substrate Solution A (Bioassay Technology Laboratory, China) and 50 μL of Substrate Solution B (Bioassay Technology Laboratory, China) were added. The plate was incubated for 10 min at 37˚C. 50 μL of Stop solution (Bioassay Technology Laboratory, China) was added to each well. The optical density read immediately using a microplate reader set at 450 nm wavelength.</p></sec><sec id="s2_5"><title>2.5. Statistical Analyses</title><p>Data collected were analyzed using SPSS version 20 and subjected to one-way Analysis of Variance (ANOVA) in a completely randomized design. Significant means were separated. Using Duncan multiple range Test was and a P value less than 0.05 was considered significant.</p></sec></sec><sec id="s3"><title>3. Results</title><p>IFNγ: With respect to the effect of dosage of AEGL, there were significant differences (P &lt; 0.05) in IFN γ levels amongst the treatment groups (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The IFN-γ levels (574.25 pg/ml) in rabbits in Group 4 (administered 400 mg/kg AEGL) were higher (P &lt; 0.05) than those of the control and other treatment groups. The effect of time was significant (P &lt; 0.05) on IFN-γ levels declining from 621.20 pg/ml (baseline) to 306.56 pg/ml (day 28).</p><p>The trend as seen in Group 1 reveals an undulating trend as IFN γ levels decreased (P &lt; 0.05) from Day 0 to Day 7 in all treatment groups (1 - 5), increased from day 7 to day 14 (Groups 1, 2, 3 and 5), decreased from Day 14 to 21 (Groups 1, 3, 4 and 5) and an increase from day 21 to day 28 (Groups 1, 4 and 5). <xref ref-type="fig" rid="fig1">Figure 1</xref> also reveals high baseline values of IFNγ for Group 3 (713.3 pg/ml) and Group 4 (1119 pg/ml). Group 4 had the highest (P &lt; 0.05) value compared to other treatment groups. Put together, the results suggest IFNγ levels reduced significantly (P &lt; 0.05) from Day 0 to Day7 across all the groups.</p><p>IL 10: The effect of AEGL dosage on IL-10 was not significant (P &gt; 0.05) as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. However, levels seen in groups 3, 4 and 5 (administered 200, 400 and 600 mg/kg AEGL, respectively) were higher than those of the control groups (Group 1 and 2). The effect of time was significant (P &lt; 0.05) on Il-10 levels declining from 235.15 pg/ml (baseline) to 126.90 pg/ml (day 7) and 152.39 pg/ml (day 21).</p><p>The trend seen in <xref ref-type="fig" rid="fig2">Figure 2</xref> reveals that Group 4 maintains a steady decline from baseline levels to Day 14. However, undulating trends are observed as cytokine levels decrease from Day 0 to Day 7 (groups 2, 3, 4 &amp; 5) increase from Day 7 to Day 14 (groups 1, 2, 3 &amp; 5), decrease from day 14 to 21 (Group 1, 3 and 5) and increase from day 21 to 28 (groups 1, 3 and 4). Group 1 increases from baseline value, peaked at Day 14 and declines. <xref ref-type="fig" rid="fig2">Figure 2</xref> also reveals that highest (P &lt; 0.05) baseline values of 395 pg/ml were recorded in Group 4. A significant reduction in IL10 activity over a 14-day period suggests that the greatest IL10-inhibitory activity occurred at 400 mg/kg of AEGL when administered for 14 days. At 400 mg/kg, AEGL showed a stronger IL10-inhibitory activity than 0.33 ml/kg of Multivitamins (Group 2) whose activity only lasted for 7 days.</p><p>CD3: The effect of AEGL dosage on CD3 was not significant (P &gt; 0.05) as seen in <xref ref-type="fig" rid="fig3">Figure 3</xref>. The effect of time was significant (P &lt; 0.05) on CD3 levels declining from 884.60 pg/ml (baseline) to 51.16 pg/ml (day 21)</p><p>The trend in <xref ref-type="fig" rid="fig3">Figure 3</xref> reveals that the baseline values for CD3 in Group 3 (1259.8 pg/ml), Group 4 (1065 pg/ml) and Group 5 (1248.5 pg/ml) were comparably higher (P &lt; 0.01) than those of other treatment groups. A decline (P &lt; 0.01) in CD3 levels was seen from day 0 to 7 in groups 2, 3, 4 and 5 until Day 14 .CD3 levels in groups 2 and 3 remained undetectable from days 14 to 21. All groups showed recovery from day 21. Group 1 showed an opposite trend to all the other groups till day 21.</p><p>CD56: The effect of AEGL dosage on CD56 was not significant (P &gt; 0.05) as shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>. The effect of time was significant (P &lt; 0.05) on CD56 levels</p><p>declining from 1056.87 pg/ml (baseline) to 676.84 pg/ml (day 21). Is the archetypal immunophenotypic marker of natural killer cells and triggers effector functions such as cytotoxicity and T helper 1 cytokine production (Van Acker et al., 2017). <xref ref-type="fig" rid="fig4">Figure 4</xref> shows that the highest CD56-inhibition is at 400 mg/kg.</p><p>Trend seen showed a marked drop (P &lt; 0.01) in CD56 levels from day 0 to 7 in all treatment groups. This was successively followed by an increase in cytokine levels (P &lt; 0.01) in groups 1, 2, 3 and 4 from days 7 to 14. Days 14 - 21 was characterized by a decline in CD56 levels while days 21 to 28 was seen in groups 1, 3, 4 and 5.</p></sec><sec id="s4"><title>4. Discussion</title><p>IFNγ: Certain bioactive compounds contained in Gongronema latifolium have anti-inflammatory and antioxidant activities [<xref ref-type="bibr" rid="scirp.120913-ref11">11</xref>]. Like several other plant extracts [<xref ref-type="bibr" rid="scirp.120913-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref15">15</xref>], AEGL can be used for the treatment of inflammation as they have been proven to decrease IFN-γ activity. The down regulation of the expression of TNF-α/IFN-γ through the blockade of several pathways is associated with the inhibition of ERK1/2 phosphorylation [<xref ref-type="bibr" rid="scirp.120913-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref16">16</xref>].</p><p>It has been shown that many plants with anti-inflammatory effect could also some antibacterial properties [<xref ref-type="bibr" rid="scirp.120913-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref18">18</xref>]. The roughages taken by Group1, Tridax pubscens and the multivitamins taken by Group 2 could also reduce IFN γ levels by their anti-inflammatory activity [<xref ref-type="bibr" rid="scirp.120913-ref19">19</xref>]. An upward significant (P &lt; 0.05) trend in seen Group 3 from Days 7 and 14 is suggestive of an NKC-derived IFN γ production. Like bitter gourd (Momordica charantia) juice and the 70% hydro-methanolic extract of Dioscorea alata, AEGL may also show pro-inflammatory activity by increasing IFN γ production [<xref ref-type="bibr" rid="scirp.120913-ref20">20</xref>]. IFNγ produced by NKC has been shown to have cytotoxic activity [<xref ref-type="bibr" rid="scirp.120913-ref21">21</xref>].</p><p>Over the 28-day period, IFNγ production is most significantly (P &lt; 0.05) altered in Group 4 (400 mg/kg of AEGL). IFNγ levels reduced from 1119 pg/ml to 332 pg/ml in a 21-day period showing the greatest inhibitory activity. This suggests a maximum effective dose of 400 mg/kg of AEGL administered at 21 days. High baseline values for Group 3 and 4 might be suggestive of a pre-existing inflammatory state where macrophages are activated which in turn trigger the production of Th1-derived IFNγ [<xref ref-type="bibr" rid="scirp.120913-ref22">22</xref>].</p><p>IL-10: Results suggests that AEGL is a natural inhibitor of IL10. In a similar fashion, Rituximab, a chimeric mouse antihuman CD20 antibody, inhibits IL10 resulting in the down regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis caused by chemotherapeutic drugs [<xref ref-type="bibr" rid="scirp.120913-ref23">23</xref>]. IL10 is an immunosuppressive cytokine which directly affect NKC count. Elevated IL10 levels in a tumor microenvironment, suppresses IL12 which is the main stimulator of NKC production and it also down-regulates the expression TNF, and IFN-γ [<xref ref-type="bibr" rid="scirp.120913-ref23">23</xref>]. On the contrary, with low IL10 levels, IL12 is increased and this increases NKC cytotoxicity [<xref ref-type="bibr" rid="scirp.120913-ref24">24</xref>].</p><p>CD3: CD3 is an important and highly specific immunohistochemical marker for all subtypes of T-cells including immature T cells like pro-thymocytes and thymocytes. It is also marker for T cell lymphomas (differentiating them from B cell lymphomas) and leukemia [<xref ref-type="bibr" rid="scirp.120913-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref26">26</xref>]. CD3 binds with subunits of TCR (alpha/beta ligand binding subunits) to form a complex that triggers signal transduction. Ligand binding with this complex induces conformational change of CD3 and recruits Nck adaptor protein [<xref ref-type="bibr" rid="scirp.120913-ref27">27</xref>]. The CD3 result shows the treated control and other treated groups caused the inhibition of CD3 T-cell proliferation. This might be due to the presence of common compounds such as Vitamin D. 1, 25-dihydroxyvitamin D3 which has been shown to inhibit the proliferation of T lymphocytes [<xref ref-type="bibr" rid="scirp.120913-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref28">28</xref>].</p><p>CD56: is neural cell adhesion molecule. It is a typical example of phenotypic marker of natural killer cells and so cytotoxicity. The 400 mg/kg AEGL had the most significant up-regulatory effects on the marker (P &lt; 0.05). The does may serve to for the detection of cytotoxicity.</p><p>Though known for its remarkable antioxidant and NKC stimulatory properties, the administration of 0.33 ml of multivitamins per kg live weight did not show enough potency as compared with 400 mg/kg of AEGL. High baseline values in groups 3 and 4 could be suggestive of an inflammatory process. Group 3 showed the highest inhibition of T cell activation while Group 4 showed the highest NK cell activity. However, it is important to note that the results and the interpretations may have been negatively affected by several factors which include the complex cytokine network interactions, nature of cytokines, genetic differences, experimental methodology and sample related issues [<xref ref-type="bibr" rid="scirp.120913-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.120913-ref30">30</xref>].</p><p>Established Facts:</p><p>• Gongronema latifolium is a perennial edible plant with soft and pliable stem</p><p>• Medicinal plants, including Gongronema latifolium, have anti-inflammatory activity</p><p>• Medicinal plants have been used from the ancient times for human health benefits</p><p>Highlights of the findings and novelties:</p><p>• At 400 mg/kg for 21 days in rabbits, AEGL showed very strong anti-inflammatory activity against all the cytokines and cell surface markers</p><p>• The molecular mechanism is through the expression of IFNγ and IL-10 cytokines via the expression of CD3 and CD56 cellular sources</p><p>• Administration of 0.33 ml of multivitamins per kg live weight did not show enough potency as compared with 400 mg/kg of AEGL</p></sec><sec id="s5"><title>5. Conclusion</title><p>In general, the production of all the cytokines was affected in time while IFN-γ levels increased in a dose-dependent manner following the administration of AEGL. IFNγ showed significant anti-inflammatory and pro-inflammatory activities because of their pleiotropic nature. The rabbits that received 400 mg/kg for all the cytokines exhibited significant activity which is suggestive of the maximum effective dose for AEGL (21 days for IFNγ and 14 days for IL10).</p></sec><sec id="s6"><title>Acknowledgements</title><p>Authors wish to acknowledge the management of Nigerian Institute of Pharmaceutical Research and Development (NIPRD) for permission to use the institutions facility to run the studies.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>Authors declare, there is no conflict of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Rowaiye, A.B., Njoku, M., Oli, A.N., Igbokwe, N.H., Asala, T., Salami, S.A., Uzochukwu, I.C. and Esimone, C.O. (2022) Aqueous Leaves Extract of Gongronema latifolium (Benth) Downregulates the Expression of IFN-γ, IL-10 and Cell Surface Markers in Rabbits. Open Journal of Medical Microbiology, 12, 117-128. https://doi.org/10.4236/ojmm.2022.124011</p></sec><sec id="s9"><title>List of Abbreviations</title><p>Natural Killer Cell (NKC)</p><p>Aqueous extract of Gongronema latifolium (AEGL)</p><p>Enzyme-linked immunosorbent assay (ELISA)</p><p>National Institute for Pharmaceutical Research and Development (NIPRD)</p><p>Horseradish peroxidase (HRP)</p><p>Standard error in the mean (SEM)</p><p>Analysis of Variance (ANOVA)</p></sec></body><back><ref-list><title>References</title><ref id="scirp.120913-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Scully, C., Georgakopoulou, E.A. and Hassona, Y. (2017) The Immune System: Basis of So Much Health and Disease: 4. Immunocytes. Dental Update, 44, 436-438, 441-442. https://doi.org/10.12968/denu.2017.44.5.436</mixed-citation></ref><ref id="scirp.120913-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sahlmann, C.O. and Str&amp;#246bel, P. (2016) Pathophysiologie der Entzündung [Pathophysiology of Inflammation]. Nuklearmedizin, 55, 1-6. https://doi.org/10.1055/s-0037-1616468</mixed-citation></ref><ref id="scirp.120913-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Maroon, J.C., Bost, J.W. and Maroon, A. (2010) Natural Anti-Inflammatory Agents for Pain Relief. Surgical Neurology International, 1, Article No. 80. https://doi.org/10.4103/2152-7806.73804</mixed-citation></ref><ref id="scirp.120913-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rowaiye, A.B., Onuh, O.A., Oli, A.N., Okpalefe, O.A., Oni, S. and Nwankwo, E.J. (2020) The Pandemic COVID-19: A Tale of Viremia, Cellular Oxidation and Immune Dysfunction. The Pan African Medical Journal, 36, Article No. 188. https://doi.org/10.11604/pamj.2020.36.188.23476</mixed-citation></ref><ref id="scirp.120913-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chaplin, D.D. (2010) Overview of the Immune Response. The Journal of Allergy and Clinical Immunology, 125, S3-S23. https://doi.org/10.1016/j.jaci.2009.12.980</mixed-citation></ref><ref id="scirp.120913-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Iyer, S.S. and Cheng, G. (2012) Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune Disease. Critical Reviews in Immunology, 32, 23-63. https://doi.org/10.1615/CritRevImmunol.v32.i1.30</mixed-citation></ref><ref id="scirp.120913-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Burmeister, A.R. and Marriott, I. (2018) The Interleukin-10 Family of Cytokines and Their Role in the CNS. Frontiers in Cellular Neuroscience, 12, Article No. 458. https://doi.org/10.3389/fncel.2018.00458</mixed-citation></ref><ref id="scirp.120913-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Carey, A.J., Tan, C.K. and Ulett, G.C. (2012) Infection-Induced IL-10 and JAK-STAT: A Review of the Molecular Circuitry Controlling Immune Hyperactivity in Response to Pathogenic Microbes. JAK-STAT, 1, 159-167. https://doi.org/10.4161/jkst.19918</mixed-citation></ref><ref id="scirp.120913-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zaidi, M.R. (2019) The Interferon-Gamma Paradox in Cancer. Journal of Interferon &amp; Cytokine Research, 39, 30-38. https://doi.org/10.1089/jir.2018.0087</mixed-citation></ref><ref id="scirp.120913-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ribeiro, E.B., de Marchi, P.G.F., Honorio-Fran&amp;#231;a, A.C., Fran&amp;#231;a, E.L. and Soler, M.A.G. (2020) Interferon-Gamma Carrying Nanoemulsion with Immunomodulatory and Anti-Tumor Activities. Journal of Biomedical Materials Research Part A, 108, 234-245. https://doi.org/10.1002/jbm.a.36808</mixed-citation></ref><ref id="scirp.120913-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Agwaramgbo, A., Ilodigwe, E.E., Ajaghaku, D.L., Onuorah, M.U. and Mbagwu, S.I. (2014) Evaluation of Antioxidant, Immunomodulatory Activities, and Safety of Ethanol Extract and Fractions of Gongronema latifolium Fruit. International Scholarly Research Notices, 2014, Article ID: 695272. https://doi.org/10.1155/2014/695272</mixed-citation></ref><ref id="scirp.120913-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Council for International Organization of Medical Sciences and The International Council for Laboratory Animal Science (2012) International Guiding Principles for Biomedical Research Involving Animals. CIOMS &amp; ICLAS, Geneva.</mixed-citation></ref><ref id="scirp.120913-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ajeigbe, K.O., Enitan, S.S., Omotoso, D.R. and Oladokun, O.O. (2013) Acute Effects of Aqueous Leaf Extract of Aspilia africana C.D. Adams on Some Haematological Parameters in Rats. African Journal of Traditional, Complementary, and Alternative Medicines, 10, 236-243. https://doi.org/10.4314/ajtcam.v10i5.4</mixed-citation></ref><ref id="scirp.120913-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nunes, T.R.S., Cordeiro, M.F., Beserra, F.G., de Souza, M.L., da Silva, W.A.V., Ferreira, M.R.A., Soares, L.A.L., Costa-Junior, S.D., Cavalcanti, I.M.F., Pitta, M.G.D.R., Pitta, I.D.R. and Rêgo, M.J.B.M. (2018) Organic Extract of Justicia pectoralis Jacq. Leaf Inhibits Interferon-γ Secretion and Has Bacteriostatic Activity against Acinetobacter baumannii and Klebsiella pneumoniae. Evidence-Based Complementary and Alternative Medicine, 2018, Article ID: 5762368. https://doi.org/10.1155/2018/5762368</mixed-citation></ref><ref id="scirp.120913-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zang, N., Xie, X., Deng, Y., Wu, S., Wang, L., Peng, C., Li, S., Ni, K., Luo, Y. and Liu, E. (2011) Resveratrol-Mediated Gamma Interferon Reduction Prevents Airway Inflammation and Airway Hyperresponsiveness in Respiratory Syncytial Virus-Infected Immunocompromised Mice. Journal of Virology, 85, 13061-13068. https://doi.org/10.1128/JVI.05869-11</mixed-citation></ref><ref id="scirp.120913-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sung, Y.Y., Kim, Y.S. and Kim, H.K. (2012) Illicium verum Extract Inhibits TNF-α- and IFN-γ-Induced Expression of Chemokines and Cytokines in Human Keratinocytes. Journal of Ethnopharmacology, 144, 182-189. https://doi.org/10.1016/j.jep.2012.08.049</mixed-citation></ref><ref id="scirp.120913-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Parameswari, P., Devika, R. and Vijayaraghavan, P. (2019) In Vitro Anti-Inflammatory and Antimicrobial Potential of Leaf Extract from Artemisia nilagirica (Clarke) Pamp. Saudi Journal of Biological Sciences, 26, 460-463. https://doi.org/10.1016/j.sjbs.2018.09.005</mixed-citation></ref><ref id="scirp.120913-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Allegra, M. (2019) Antioxidant and Anti-Inflammatory Properties of Plants Extract. Antioxidants (Basel), 8, Article No. 549. https://doi.org/10.3390/antiox8110549</mixed-citation></ref><ref id="scirp.120913-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lounder, D.T., Khandelwal, P., Dandoy, C.E., Jodele, S., Grimley, M.S., Wallace, G., Lane, A., Taggart, C., Teusink-Cross, A.C., Lake, K.E. and Davies, S.M. (2017) Lower Levels of Vitamin A Are Associated with Increased Gastrointestinal Graft-versus- Host Disease in Children. Blood, 129, 2801-2807. https://doi.org/10.1182/blood-2017-02-765826</mixed-citation></ref><ref id="scirp.120913-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dey, P. and Chaudhuri, T.K. (2014) In Vitro Modulation of TH1 and TH2 Cytokine Expression by Edible Tuber of Dioscorea alata and Study of Correlation Patterns of the Cytokine Expression. Food Science and Human Wellness, 3, 1-8. https://doi.org/10.1016/j.fshw.2014.01.001</mixed-citation></ref><ref id="scirp.120913-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wang, R., Jaw, J.J., Stutzman, N.C., Zou, Z. and Sun, P.D. (2012) Natural Killer Cell-Produced IFN-γ and TNF-α Induce Target Cell Cytolysis through Up-Regulation of ICAM-1. Journal of Leukocyte Biology, 91, 299-309. https://doi.org/10.1189/jlb.0611308</mixed-citation></ref><ref id="scirp.120913-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Muraille, E., Leo, O. and Moser, M. (2014) TH1/TH2 Paradigm Extended: Macrophage Polarization as an Unappreciated Pathogen-Driven Escape Mechanism? Frontiers in Immunology, 5, Article No. 603. https://doi.org/10.3389/fimmu.2014.00603</mixed-citation></ref><ref id="scirp.120913-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, S., Wu, D., Wu, P., Wang, Z. and Huang, J. (2015) Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. PLOS ONE, 10, e0139598. https://doi.org/10.1371/journal.pone.0139598</mixed-citation></ref><ref id="scirp.120913-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Szkaradkiewicz, A., Karpiński, T.M., Drews, M., Borejsza-Wysocki, M., Majewski, P. and Andrzejewska, E. (2010) Natural Killer Cell Cytotoxicity and Immunosuppressive Cytokines (IL-10, TGF-beta1) in Patients with Gastric Cancer. Journal of Biomedicine and Biotechnology, 2010, Article ID: 901564. https://doi.org/10.1155/2010/901564</mixed-citation></ref><ref id="scirp.120913-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">J&amp;#281;drych, M., Wawryk-Gawda, E., Jod&amp;#322;owska-J&amp;#281;drych, B., Chylińska-Wrzos, P. and Jasiński, L. (2013) Immunohistochemical Evaluation of Cell Proliferation and Apoptosis Markers in Ovarian Surface Epithelial Cells of Cladribine-Treated Rats. Protoplasma, 250, 1025-1034. https://doi.org/10.1007/s00709-012-0461-z</mixed-citation></ref><ref id="scirp.120913-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Sheikhpour, R., Pourhosseini, F., Neamatzadeh, H. and Karimi, R. (2017) Immunophenotype Evaluation of Non-Hodgkin’s Lymphomas. Medical Journal of The Islamic Republic of Iran, 31, 804-807. https://doi.org/10.14196/mjiri.31.121</mixed-citation></ref><ref id="scirp.120913-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Khoo, A.L., Joosten, I., Michels, M., Woestenenk, R., Preijers, F., He, X.H., Netea, M.G., van der Ven, A.J. and Koenen, H.J. (2011) 1,25-Dihydroxyvitamin D3 Inhibits Proliferation but Not the Suppressive Function of Regulatory T Cells in the Absence of Antigen-Presenting Cells. Immunology, 134, 459-468. https://doi.org/10.1111/j.1365-2567.2011.03507.x</mixed-citation></ref><ref id="scirp.120913-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Corripio-Miyar, Y., Mellanby, R.J., Morrison, K. and McNeilly, T.N. (2017) 1,25- Dihydroxyvitamin D3 Modulates the Phenotype and Function of Monocyte Derived Dendritic Cells in Cattle. BMC Veterinary Research, 13, Article No. 390. https://doi.org/10.1186/s12917-017-1309-8</mixed-citation></ref><ref id="scirp.120913-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Rowaiye, A.B., Asala, T., Oli, A.N., Uzochukwu, I.C., Akpa, A. and Esimone, C.O. (2020) The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials. Current Drug Targets, 21, 1733-1751. https://doi.org/10.2174/1389450121666200910160929</mixed-citation></ref><ref id="scirp.120913-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Rowaiye, A.B., Njoku, M.O., Oli, A.N., Akramid, S., Asala, T., Uzochukwu, I.C., Akpa, A., Saki, M. and Esimone, C.O. (2021) In Vivo Effects of Aqueous Extract of Gongronema latifolium Benth on the Tumor Necrosis Factor-α, Transforming Growth Factor-β, and Hepatic Enzymes. Oncologie, 23, 547-557. https://doi.org/10.32604/oncologie.2021.019738</mixed-citation></ref></ref-list></back></article>